Results 11 to 20 of about 509,312 (356)

In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and LimitationsSummary

Cellular and Molecular Gastroenterology and Hepatology, 2023
Liver fibrosis is a common result of liver injury owing to various kinds of chronic liver diseases. A deeper understanding of the pathophysiology of liver fibrosis and identifying potential therapeutic targets of liver fibrosis is important because liver
Young-Sun Lee, Ekihiro Seki
doaj   +1 more source

Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease

Diagnostics, 2021
Liver fibrosis predicts liver-related and cardiovascular outcomes in chronic liver disease patients. We compared the diagnostic performance of various liver fibrosis biomarkers for identifying histological significant/advanced fibrosis. Additionally, the
Stefano Ballestri, Alessandro Mantovani, Enrica Baldelli, Simonetta Lugari, Mauro Maurantonio, Fabio Nascimbeni, Alessandra Marrazzo, Dante Romagnoli, Giovanni Targher, Amedeo Lonardo   +9 more
doaj   +1 more source

Inhibiting IRE1α-endonuclease activity decreases tumor burden in a mouse model for hepatocellular carcinoma

eLife, 2020
Hepatocellular carcinoma (HCC) is a liver tumor that usually arises in patients with cirrhosis. Hepatic stellate cells are key players in the progression of HCC, as they create a fibrotic micro-environment and produce growth factors and cytokines that ...
Nataša Pavlović, Carlemi Calitz, Kess Thanapirom, Guiseppe Mazza, Krista Rombouts, Pär Gerwins, Femke Heindryckx   +6 more
doaj   +1 more source

Assessment and validation of the TREAT-B score to assess the treatment eligibility of patients with chronic hepatitis B virus infection

Frontiers in Medicine, 2022
Background and aimsAccess to Hepatitis B virus (HBV) DNA testing to determine treatment eligibility is limited in low-income countries. Therefore, this study aimed to assess and validate the TREAT-B score proposed as the treatment threshold in an Asian ...
Kessarin Thanapirom, Kessarin Thanapirom, Kessarin Thanapirom, Sirinporn Suksawatamnuay, Sirinporn Suksawatamnuay, Sirinporn Suksawatamnuay, Panarat Thaimai, Panarat Thaimai, Panarat Thaimai, Sombat Treeprasertsuk, Piyawat Komolmit, Piyawat Komolmit, Piyawat Komolmit, Pisit Tangkijvanich   +13 more
doaj   +1 more source

Combi-Elasto Evaluation of the Degree of Liver Fibrosis in Children with Cholestatic Liver Disease

Diagnostics, 2023
Cholestatic liver disease is a common liver disease in infants and young children. Liver fibrosis is a key factor affecting the prognosis, and liver transplantation is the only treatment option for liver cirrhosis.
Rina Li, Caihui Hu, Fenglin Xu, Qi Zhang, Fazhi Zhou, Chenpeng Zheng, Yang Gao, Yi Tang, Jingyu Chen   +8 more
doaj   +1 more source

The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Biomedicines, 2022
Liver fibrosis is a key pathophysiology process in chronic liver disease. It is still unclear whether the impact of liver fibrosis is not fully realized in type 2 diabetes mellitus (T2D) patients with nonalcoholic fatty liver disease (NAFLD), and the ...
Chia-Yen Dai, Tzu-Jung Fang, Wei-Wen Hung, Hui-Ju Tsai, Yi-Chun Tsai   +4 more
doaj   +1 more source

Modulation of the unfolded protein response by tauroursodeoxycholic acid counteracts apoptotic cell death and fibrosis in a mouse model for secondary biliary liver fibrosis [PDF]

, 2017
The role of endoplasmic reticulum stress and the unfolded protein response (UPR) in cholestatic liver disease and fibrosis is not fully unraveled. Tauroursodeoxycholic acid (TUDCA), a hydrophilic bile acid, has been shown to reduce endoplasmic reticulum (
Bogaerts, Eliene, Colle, Isabelle, Devisscher, Lindsey, Geerts, Anja, Hoorens, Anne, Paridaens, Annelies, Raevens, Sarah, van Grunsven, Leo, Van Vlierberghe, Hans, Verhelst, Xavier   +9 more
core   +5 more sources

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S   +12 more
core   +3 more sources

M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes. [PDF]

, 2017
Acute injury in the setting of liver fibrosis is an interesting and still unsettled issue. Most recently, several prominent studies have indicated the favourable effects of liver fibrosis against acute insults.
Bai, Li, Chen, Yu, Duan, Zhongping, Han, Yuan-Ping, Hu, Richard, Kong, Ming, Liu, Shuang, Liu, Xin, Lou, Jinli, Pandol, Stephen J, Ren, Feng, Zhang, Xiaohui, Zheng, Qingfen, Zheng, Sujun   +13 more
core   +2 more sources

Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B [PDF]

, 2005
Background: HBV infection is a serious global heath problem. It is crucial to monitor this disease more closely with a non-invasive marker in clinical trials.
Derakhshan, M.H., Estakhri, A., Malekzadeh, R., Mohamadnejad, M., Mohammadkani, A., Montazeri, F., Montazeri, G., Nouri, N., Samiee, S., Zamani, F.   +9 more
core   +4 more sources